Want to track V3Vd and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
V3Vd is not paying dividends to its shareholders.
The last earnings report, released on May 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0352%, based on the last three reports.
FamiCord AG has completed 1 stock splits, with the recent split occurring on Jul 14, 2017.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XETRA (EUR).
FamiCord AG (V3Vd) FAQ
On which exchange is it traded?
FamiCord AG is listed on CBOE.
What is its stock symbol?
The ticker symbol is V3Vd.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.64%.
What is its market cap?
As of today, no market cap data is available.
Has FamiCord AG ever had a stock split?
FamiCord AG had 1 splits and the recent split was on Jul 14, 2017.
FamiCord AG Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Jakub Julian Baran CEO | CBOE Exchange | DE000A0BL849 ISIN |
| Germany Country | 771 Employees | 5 Jun 2019 Last Dividend | - Last Split | - IPO Date |
FamiCord AG is a leading European company specializing in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood, cord tissue, and postnatal tissues. Headquartered in Leipzig, Germany, and founded in 1997 as Vita 34 AG, it rebranded to FamiCord AG in February 2025 following mergers with entities like Polish PBKM, forming Europe's largest stem cell bank with over 1,000,000 stored units. Operating through segments such as Vita 34 and PBKM, the company serves families across Germany, Poland, Portugal, and internationally, including expansions to Dubai, the UK, Middle East, and Asia. FamiCord AG develops advanced therapies, including CAR-T cells and viral vectors for cancer treatment, genetic tests, and biobanking services like sperm freezing and adipose tissue storage. It partners with over 1,500 clinics, enabling more than 8,000 patient treatments and 260 cord blood transplantations, while providing biotech solutions in regenerative medicine. With 771 employees, FamiCord AG plays a pivotal role in the healthcare sector, bridging stem cell preservation with innovative cellular therapies.
Contact Information
Address: Perlickstrasse 5
Phone: 49 341 48792 5500
Website: https://www.famicord.com
